+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Therapies - Global Strategic Business Report

  • PDF Icon

    Report

  • 590 Pages
  • December 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 834980
The global market for Cancer Therapies is estimated at US$190.9 Billion in 2023 and is projected to reach US$382.0 Billion by 2030, growing at a CAGR of 10.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the cancer therapies market is driven by several factors. Advances in biotechnology and genomics have led to the development of novel therapies and personalized treatment approaches, significantly expanding the range of options available to patients. The increasing prevalence of cancer worldwide, partly due to aging populations and lifestyle factors, is fueling demand for effective treatments. Moreover, substantial investment in cancer research by pharmaceutical companies and government agencies is accelerating the discovery and development of new therapies. The rising awareness and early diagnosis of cancer are also contributing to market growth, as early-stage cancers are more treatable with modern therapies.

Additionally, regulatory approvals of new and innovative treatments are providing more options for patients and clinicians. The expansion of healthcare infrastructure, particularly in emerging economies, is making advanced cancer therapies more accessible to a broader population. Collaborations and partnerships among biotech firms, research institutions, and healthcare providers are fostering innovation and facilitating the commercialization of cutting-edge cancer treatments.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Chemotherapy segment, which is expected to reach US$112.8 Billion by 2030 with a CAGR of a 8.9%. The Targeted Therapy segment is also set to grow at 11.3% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $74.6 Billion in 2023, and China, forecasted to grow at an impressive 12.8% CAGR to reach $35.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Cancer Therapies Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cancer Therapies Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Cancer Therapies Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AbbVie Inc., Alaunos Therapeutics, Inc., Amgen Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 109 Featured):

  • AbbVie Inc.
  • Alaunos Therapeutics, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Glaxosmithkline Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth in Cancer Therapies Market
  • Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market
  • By Cancer Type
  • Select Cancer Stats
  • Total Number of New Cancer Cases by Type: 2022
  • Total Number of Cancer Deaths by Type: 2022
  • Cancer Incidence by Region: 2022
  • Cancer Mortality by Region: 2022
  • Global Economic Update
  • Flat Growth for 2024 & A Possible Soft Landing, as the Global Economy Attempts to Balance Recovery While Navigating Through Wars, Political Conflicts & Inflation: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2022 Through 2025
  • Cancer Therapies - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Research Continues to Unravel Complexities of Cancer
  • Evolution of Oncology Therapeutics: A Three-Decade Perspective on FDA Approvals
  • Select Cancer Drugs Approved by FDA in 2023 & 2024
  • Select Phase IV Clinical Trials Involving Cancer Drugs (2023)
  • Select Phase III Clinical Trials Involving Cancer Drugs (2023)
  • Select Leading Cancer Drugs Worldwide by Sales: 2022
  • Overview of Cancer Therapy Segments
  • Recent Market Activity
  • Influencer/Product/Technology Insights
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Key Advancements in Cancer Treatment to Shape Future Landscape
  • Integration of Stem Cell Research Marks Next Generation of Oncological Therapies
  • Use of Artificial Intelligence for Treating Cancer Patients Witness a Surge
  • Challenges and Future Prospects
  • Immunotherapies to Transform Cancer Care
  • Cancer Immunotherapy Moves to Next Level
  • Potential for CAR T Cell Therapies In Solid Tumors
  • Cancer-on-chip models Gains Attention in immunotherapy
  • Antibody-drug conjugates (ADCS), a Novel Class of Therapeutics Poised to Address the Challenges of Treating Difficult-To-Treat Cancers
  • Novel Drugs & Drug Modifications
  • Chemotherapy Drugs: A Key Weapon in Cancer Treatment
  • Targeted Cancer Therapies: Precision Medicine in Oncology
  • Advances for Precise Tumor Targeting
  • Select Approved Targeted Therapies for Various Types of Cancers
  • Expanding Horizons: The Growth of the Cancer Gene Therapy Market
  • Extending the Success of Cell And Gene Therapy From Blood Cancers To Solid Tumors
  • Vaccines: A Promising Future Area of Cancer Therapeutics
  • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
  • Nanovectors: Pioneering the Future of Cancer Treatment
  • Drug Delivery Employing AI and Nanorobots
  • Personalized Medicine Gains Importance
  • Integration of Artificial Intelligence (AI) in Development of Personalized Cancer Treatment: A Novel Approach
  • Increasing Application of Digital Technologies Pave Way for Timely Treatment of Cancer Patients
  • Patent Expiries of Branded Drugs to Trigger Generic Competition
  • Cancer Types, Approved and Pipeline Drugs
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cancer Therapies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Gastrointestinal Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Gynecologic Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
CANADA
JAPAN
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
CHINA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
EUROPE
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
FRANCE
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
GERMANY
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
ITALY
UNITED KINGDOM
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
AUSTRALIA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned

  • AbbVie Inc.
  • Alaunos Therapeutics, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Glaxosmithkline Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Table Information